Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.78 -2.64%

-$0.05 today

Market cap
$792.52M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.42M

Average 2.48M

Returns on capital

Lexicon Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-46.8%

avg -72.4%

ROIC

-28.7%

avg -40.5%

ROA

-27.2%

avg -35.3%

Analysis

ROA is currently the strongest return metric at -27.2% versus its period average of -35.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Michael Exton

Chief Executive Officer & DirectorUSD 1.15M56328.50K0.07%

Craig Granowitz

Senior Vice President & Chief Medical OfficerUSD 789.54K61——

Brian T. Crum

Senior Vice President, General Counsel & SecretaryUSD 687.37K530<0.01%

Scott Coiante

Senior Vice President & Chief Financial OfficerUSD 646.29K59——

Wendy E. McDermott

Senior Vice President of Human ResourcesUSD 580.45K55——

Kristen L. Alexander

Vice President of Finance & AccountingUSD 379.81K58——

Suma Gopinathan

Senior Vice President of Discovery—530<0.01%

Lisa DeFrancesco

Senior Vice President of Investor Relations & Corporate Communications—4624.67K<0.01%

Rachel Yap Martens

Senior Vice President & Chief Commercial Officer—4231.26K<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

9

$2.77M

Sells

0

$0.00

Net Transaction Value

+$2.77M

Net buying

Most Active

DEBBANE RAYMOND

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 6, 26

Exton Michael

Direct

Buy$50K
Feb 25, 26

DEBBANE RAYMOND

Direct

Buy$3K
Feb 23, 26

DEBBANE RAYMOND

Direct

Buy$147K
Feb 20, 26

DEBBANE RAYMOND

Direct

Buy$147.8K
Feb 19, 26

DEBBANE RAYMOND

Direct

Buy$72K
Feb 18, 26

DEBBANE RAYMOND

Direct

Buy$176.5K
Feb 17, 26

DEBBANE RAYMOND

Direct

Buy$100.5K
Feb 13, 26

DEBBANE RAYMOND

Direct

Buy$75.9K
Feb 2, 26

Invus Global Management, LLC

Indirect

Buy$2M

Summary

Insiders reported 9 buys worth $2.77M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.77M. DEBBANE RAYMOND was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+610.3%
+39.1% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at +610.3% over three years. Forward estimates point to Revenue at +39.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Lexicon Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about LXRX's management, answered from reported figures.

Who manages LXRX?

Lexicon Pharmaceuticals, Inc. (LXRX) lists 9 active executives. The top listed executive is Craig Granowitz, Senior Vice President & Chief Medical Officer.

Are LXRX insiders buying or selling?

Recent insider activity shows net buying of $67.48M.